STANDARD BIOTOOLS INC Stock Price, News & Analysis

Standard BioTools (NASDAQ:LAB) has scheduled its second quarter 2025 earnings conference call for August 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.

Investors can join via phone using the following dial-in numbers: (888) 346-3970 for US domestic callers and (412) 902-4297 for international callers. The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com.

Illumina (NASDAQ: ILMN) has announced a definitive agreement to acquire SomaLogic from Standard BioTools for $350 million in cash, plus up to $75 million in performance-based milestones and royalties. The acquisition builds on their existing partnership since 2021 and aims to enhance Illumina's presence in the proteomics market while advancing their multiomics strategy. SomaLogic brings approximately 250 employees and facilities in Boulder, Colorado, including a CLIA- and CAP-certified lab. The deal combines SomaLogic's proteomics expertise with Illumina's NGS platforms, with the Illumina Protein Prep currently being used by 40 early-access customers globally. The transaction is expected to close in first half of 2026, subject to regulatory approvals, and become profitable by 2027 on a non-GAAP operating income basis.

Standard BioTools (NASDAQ: LAB) has announced the strategic sale of SomaLogic to Illumina (NASDAQ: ILMN) for up to $425 million. The deal includes $350 million in upfront cash payment and potential milestone payments of up to $75 million. Standard BioTools will retain rights to Single SOMAmer reagent commercialization and receive a 2% royalty on Illumina Protein Prep kit sales for 10 years. The transaction, expected to close in H1 2026, will significantly simplify Standard BioTools' operating structure and enable adjusted EBITDA break-even. Post-closing, the company expects to have at least $550 million in cash to fuel its inorganic growth strategy through M&A, targeting underappreciated assets in life sciences with strong margin potential and recurring revenue models.

Standard BioTools (NASDAQ: LAB) has announced its inaugural Proteomics Roundtable Series, a virtual event program focusing on proteomics advancements in healthcare. The first session, scheduled for June 6, 2025, will feature experts discussing findings from the 30-year EPIC cancer study involving 500,000 participants. The series includes future sessions on comparative metrics for proteomic platforms, biobank research applications, and proteomics in drug development. Dr. Stephen Williams will host the first panel featuring experts from Imperial College London and University of Oxford. The events aim to facilitate discussions about technological advancements and real-world applications in proteomics research.

Standard BioTools (NASDAQ: LAB) reported Q1 2025 financial results with revenue of $40.8 million, down 10% year-over-year. The company achieved a 45% reduction in operating loss and 29% improvement in adjusted EBITDA. Key financial metrics include: consumables revenue of $14.5M (down 16%), instruments revenue of $7.8M (up 24%), and services revenue of $17.6M (down 16%). The company maintains a strong balance sheet with $261 million in cash and no material debt. Operating expenses decreased by 38% to $52.7M, while net loss improved by 19% to $26.0M. Standard BioTools reaffirmed its full-year 2025 revenue guidance of $165-175 million, factoring in expected NIH funding pressures in Americas academic revenue.

Standard BioTools (NASDAQ: LAB) has unveiled new proteomic product innovations at AACR 2025, including the SomaScan Select 3.7K Assay, Single SOMAmer Reagents, and the next-generation CyTOF XT PRO system.

The SomaScan Select 3.7K Assay offers 3,700 unique human protein measurements and covers 70% of FDA standard clinical biomarkers. Single SOMAmer Reagents provide access to approximately 11,000 unique DNA-based reagents for protein measurement. The CyTOF XT PRO System enables simultaneous analysis of 50-plus biomarkers with up to 4x faster throughput.

The company will host a panel discussion on April 28 titled 'Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts.' Additionally, 90 scientific posters and presentations powered by Standard BioTools' proteomic portfolio will be presented at AACR 2025.

Standard BioTools (NASDAQ: LAB) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will disclose its Q1 2025 results on Tuesday, May 6, 2025, after the market closes.

A conference call and webcast are scheduled for the same day at 4:30 p.m. ET. Investors can participate through the following dial-in numbers:

• US domestic: (888) 346-3970
• International: (412) 902-4297

The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com for future reference.

Standard BioTools (NASDAQ: LAB) has announced its participation in three major investor conferences in March 2025. The company will present at TD Cowen's 45th Annual Healthcare Conference on March 3rd at 3:10 p.m. ET, attend investor meetings at the 2025 Leerink Partners Global Healthcare Conference on March 12th, and present at KeyBanc's 5th Annual Healthcare Forum on March 19th at 4:30 p.m. ET.

All presentations will be available via webcast on the company's Investor Relations website, with recordings archived at investors.standardbio.com.

Standard BioTools (NASDAQ: LAB) reported its Q4 and full year 2024 financial results, with full-year pro forma combined revenue of $175.1 million. The company achieved significant operational improvements, including a 17% reduction in pro forma operating loss and 33% year-over-year improvement in adjusted EBITDA.

Key financial highlights include additional $10 million in operational cost reductions, totaling $90 million in synergies over 12 months, and a strong balance sheet with $295 million in cash and no material debt. The company expects to reach adjusted EBITDA positive in 2026.

Q4 2024 revenue was $46.7 million, down 9% year-over-year, with consumables revenue up 10%, instruments revenue down 25%, and services revenue down 16%. For fiscal year 2025, Standard BioTools projects revenue between $165-175 million, factoring in anticipated NIH funding pressures in Americas academic revenue.